Literature DB >> 2584670

Rapid development of pancreatitis following reuse of 6-mercaptopurine.

M S Cappell1, K M Das.   

Abstract

A patient with Crohn's disease developed acute pancreatitis 4 h after retaking one 50 mg dose of orally administered 6-mercaptopurine (6-MP). All seven previously reported patients who were rechallenged with 50 mg or more of 6-MP developed pancreatitis within 48 h. These findings suggest that 6-MP can produce pancreatitis due to an idiosyncratic immune-mediated response. Patients with this complication should not reuse 6-MP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584670     DOI: 10.1097/00004836-198912000-00017

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Current medical therapy of inflammatory bowel disease.

Authors:  Kiron M Das; Sherif A Farag
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 2.  Acute pancreatitis associated with milk allergy.

Authors:  A de Diego Lorenzo; J Robles Fornieles; T Herrero López; E Cos Arregui
Journal:  Int J Pancreatol       Date:  1992-12

Review 3.  Pancreatic disorders in inflammatory bowel disease.

Authors:  Filippo Antonini; Raffaele Pezzilli; Lucia Angelelli; Giampiero Macarri
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

Review 4.  Drug-induced pancreatitis.

Authors:  T Wilmink; T W Frick
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

Review 5.  Drug-induced pancreatitis : incidence, management and prevention.

Authors:  Anil R Balani; James H Grendell
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations.

Authors:  Dianna Wolfe; Salmaan Kanji; Fatemeh Yazdi; Pauline Barbeau; Danielle Rice; Andrew Beck; Claire Butler; Leila Esmaeilisaraji; Becky Skidmore; David Moher; Brian Hutton
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.